The Science Business and Future of Antibody Pharmaceuticals - Sir Gregory Winter - Trinity College
2.2 هزار بار بازدید -
11 سال پیش
-
Download the slide presentation :
Download the slide presentation : http://goo.gl/pbLGmc
Sir Greg Winter pioneered techniques that have led to antibody therapies for cancer, and diseases such as rheumatoid arthritis and multiple sclerosis. He has established hugely successful spin out companies, including Cambridge Antibody Technology and Domantis, and continues to develop new types of drugs. His technologies are involved in around 65 per cent of marketed antibody drugs today, including Humira and Herceptin.
While his science has gone on to be applied on an extraordinary scale, Greg sees himself foremost as an academic.He remains deeply committed to basic science, as a long-term investment in medical progress. He has argued extensively of the importance of scientists and clinicians interacting with each other and with business, free from bureaucratic fetters.
In 2012 Sir Gregory was installed as Master of Trinity College, Cambridge
Sir Greg Winter pioneered techniques that have led to antibody therapies for cancer, and diseases such as rheumatoid arthritis and multiple sclerosis. He has established hugely successful spin out companies, including Cambridge Antibody Technology and Domantis, and continues to develop new types of drugs. His technologies are involved in around 65 per cent of marketed antibody drugs today, including Humira and Herceptin.
While his science has gone on to be applied on an extraordinary scale, Greg sees himself foremost as an academic.He remains deeply committed to basic science, as a long-term investment in medical progress. He has argued extensively of the importance of scientists and clinicians interacting with each other and with business, free from bureaucratic fetters.
In 2012 Sir Gregory was installed as Master of Trinity College, Cambridge
11 سال پیش
در تاریخ 1392/06/20 منتشر شده
است.
2,285
بـار بازدید شده